We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Scientists Identify Gene Linked to Fatal Heart Condition

By Biotechdaily staff writers
Posted on 21 May 2002
A team of researchers from the Weizmann Institute of Science (Rehovot, Israel) and the Sheba Medical Center (Tel Aviv, Israel) has now identified the gene that causes polymorphic ventricular tachycardia (PVT). More...
This is a fatal heart condition, primarily affecting young children, that is characterized by a fast and irregular heartbeat, seizures, and in certain cases, sudden death.

As reported in the December 2001 issue of the American Journal of Human Genetics, researchers found that the disease is caused by a mutation in the gene known as Calsequestrin 2 (CASQ2), which plays a vital role in the contraction and relaxation of the heart. The mutation impairs the ability of the CASQ2 protein to attract and release calcium ions upon demand.

The current study focused on a Bedouin tribe in Northern Israel, where PVT had caused the death of nine children, in some cases from the same family. Initially, the researchers were faced with trying to identify the exact gene responsible for PVT from a possible 80 candidate genes. Fortunately, as the work progressed, information from the Human Genome Project became available. The newly mapped gene for CASQ2 emerged as a good prospect because this protein serves as a calcium ion reservoir in heart muscle cells. Indeed, only four months earlier a different research team had found that a mutation in the gene RYR2, which belongs to the same cellular pathway as CASQ2, also causes a form of PVT.

The researchers were able to confirm that the Bedouin children suffering from PVT had a mutation in their CASQ2 gene. While the mutation was caused by only a single base change, from G to C, in one of the DNA's nucleotides, this change caused the body to produce the positively charged amino acid histidine instead of negatively charged aspartic acid, which impairs the CASQ2 protein's ability to attract and release calcium ions, leading to heart failure.

"The new finding is expected to improve the screening for and treatment of this fatal disease, as well as opening a window to a better understanding of other heart conditions,” says Dr. Nili Avidan of the Weizmann Institute's Department of Molecular Genetics. "We believe that mutations in this and other biochemically related genes may lie behind a number of as yet largely unsolved heart disorders.”




Related Links:
Weizmann Institute of Science
Sheba Medical Center

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.